- Home
- TORO vs UNCY Comparison
TORO vs UNCY Comparison
Compare TORO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TORO | UNCY |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 145.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TORO | UNCY |
|---|---|---|
| Price | $5.33 | $8.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 248.4K | ★ 523.7K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.47 |
| 52 Week High | $8.50 | $8.74 |
Technical Indicators
Market Signals| Indicator | TORO | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 57.60 |
| Support Level | $5.06 | $5.95 |
| Resistance Level | $5.94 | $8.54 |
| Average True Range (ATR) | 0.49 | 0.44 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 17.33 | 55.04 |
Price Performance
Historical ComparisonAbout TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.